BCM
CRBP icon

BlueCrest Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

BlueCrest Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-994
Closed -$246K – 942
2017
Q1 		$246K Buy
+994
New +$244K 0.01% 574

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

BlueCrest Capital Management's CRBP Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2017, closing a stake of 994 shares — an estimated $246K sold.

BlueCrest Capital Management first reported a position in CRBP in Q1 2017 and held it in 1 quarter. The position peaked at $246K in Q1 2017. 69 funds tracked by Wall St. Rank hold CRBP as of Q2 2017.

  • BlueCrest Capital Management reported no remaining Corbus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 994 Corbus Pharmaceuticals shares in Q2 2017, an estimated $246K.
  • BlueCrest Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Corbus Pharmaceuticals position peaked at $246K in Q1 2017.
  • 69 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.